GLUCAGEN by Novo Nordisk is clinical pharmacology glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. First approved in 1998.
Drug data last refreshed 1h ago · AI intelligence enriched 1w ago
GLUCAGEN (glucagon) is a parenteral hormone that rapidly increases blood glucose concentration by mobilizing liver glycogen stores. It is used as an emergency treatment for severe hypoglycemia in patients with diabetes, particularly those unable to consume oral carbohydrates. The drug acts via glucagon receptors on hepatocytes to convert stored glycogen to glucose, with onset of action occurring within 13-20 minutes depending on route of administration.
Product approaching loss of exclusivity with modest Part D spending ($5M) and limited annual claims (14,171), indicating a niche but stable market requiring defensive commercial strategy.
CLINICAL PHARMACOLOGY Glucagon increases blood glucose concentration and is used in the treatment of severe hypoglycemia. Glucagon acts only on liver glycogen, converting it to glucose. Glucagon administered through a parenteral route relaxes smooth muscle of the stomach, duodenum, small bowel, and…
Worked on GLUCAGEN at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Trial to Investigate the Safety and the Pharmacokinetic, Pharmacodynamic Characteristics of Two BioChaperone® Glucagon Formulations Compared to Marketed GlucaGen® in Subjects With T1DM
Pharmacokinetics (PK) and Pharmacodynamics (PD) of Mayne Glucagon for Injection Compared With Glucagen® (Novo Nordisk) in Healthy Volunteers
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moGLUCAGEN represents a mature, LOE-approaching franchise with limited headcount growth and minimal clinical development pipeline. Career advancement opportunities are constrained; roles focus on defensive positioning, managed care negotiations, and transition planning rather than growth-stage innovation.